Monocyte activation test is one of the tests or examinations for the detection of pyrogens. A pyrogen is an element or the substance that creates rise in temperature in animal or in human. Pyrogens include heterogeneous class of fever with compounds obtained from microorganisms and the non-microbial elements. This type of pollution is called as a severe public health issue and can lead to symptoms from vascular modifications to death and shock. The MAT testing is essential for ensuring the optimal safety of the parenteral pharmaceutical products as well as the medical devices. The MAT test or the monocyte activation test is capable enough to detect both non-endotoxin and endotoxin pyrogens in one single test. Backed by several regulatory bodies, this strong MAT test assay generates sensitive results depending on the human immune reaction.
Monocyte Activation Test market was valued at over US$ 6.5 Mn. in 2018 and is anticipated to grow at a CAGR of 12.5% from 2019 to 2030.
The global monocyte activation test market is witnessing continuous advancements in test offerings and extensive growth in the product portfolio of major as well as local manufacturers. The growth of the global monocyte activation test market is attributed to increasing number of pharmaceutical and biotechnology industries globally, rising research and development, increased investments and surge in new drug approval activities. Additionally, a proposed ban on animal tests has resulted in reducing the use of the rabbit for pyrogen test. This is one of the significant factors that is driving the growth of monocyte activation tests globally. Increase in public and regulatory concerns about product safety further support the market growth.
Major Key Players of the Monocyte Activation Test Market are:
Merck, Thermo Fisher Scientific, Becton, Dickinson and Company, Sanquin, Charles River Laboratories International, Inc., Microcoat Biotechnologie GmbH, SOLVIAS AG and Lonza Group among others.
No comments:
Post a Comment